Objective: To study the clinical efficacy and safety of elemene injection adjuvant VAD chemotherapy. Method: Multiple myeloma patients were collected and randomLy divided into observation group given elemene injection adjuvant VAD chemotherapy and Vcontrol group given VAD chemotherapy. VCD chemotherapy using intravenous vincristine (0.4 mg)

adriamycin (9 mg)

oral dexamethasone (40 mg)

Elemene injection intravenous drip (0.4 g). Then remission

immune function and adverse reaction were observed. Result: Tcomplete remission rate (38.46% )

partial remission rate (46.25% )and CD3+(68.38±9.03)%

CD4+(47.18±8.49)%

CD4+/CD8+(2.17±0.42)

natural killer cells(NK)(9.31±1.34)%

tumor necrosis factor-α(TNF-α)(1.53±0.21)ng· L-1 levels

Improve the stability factor (92.31% ) of observation group were higher than control group;CD8+(21.75±5.68)%

Headache dizziness (23.08% )

gastrointestinal symptoms (7.69% )

renal impairment (7.69% )

liver function damage (7.69% )

heart function damage (15.38% )

bone marrow suppression (7.69% ) were significantly less thancontrol group. Conclusion: Elemene injection adjuvant VAD chemotherapy has positive clinical value for it can improve remission and immune function

reduce adverse reaction.